# EDGAR Filing Document

**Accession Number:** 0001566373
**File Stem:** 0000947871-23-000292
**Filing Date:** 2023-3
**Character Count:** 25432
**Document Hash:** 3adf555b59b1557dd011bcbb078fda33
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000947871-23-000292.hdr.sgml**: 20230306

**ACCESSION NUMBER**: 0000947871-23-000292

**CONFORMED SUBMISSION TYPE**: SC TO-T/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230306

**DATE AS OF CHANGE**: 20230306

**GROUP MEMBERS**: FENNEC ACQUISITION INC

**GROUP MEMBERS**: SINO BIOPHARMACEUTICAL LTD

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** F-star Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001566373
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 522386345
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-T/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-89626
- **FILM NUMBER:** 23707562

**BUSINESS ADDRESS:**
- **STREET 1:** 35 PARKWOOD DRIVE
- **STREET 2:** BABRAHAM RESEARCH CAMPUS
- **CITY:** CAMBRIDGE
- **STATE:** X0
- **ZIP:** CB22 3AT
- **BUSINESS PHONE:** 44 1223 497400

**MAIL ADDRESS:**
- **STREET 1:** 35 PARKWOOD DRIVE
- **STREET 2:** BABRAHAM RESEARCH CAMPUS
- **CITY:** CAMBRIDGE
- **STATE:** X0
- **ZIP:** CB22 3AT

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Spring Bank Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20130108
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Invox Pharma Ltd
- **CENTRAL INDEX KEY:** 0001932556
- **IRS NUMBER:** 000000000

**FILING VALUES:**
- **FORM TYPE:** SC TO-T/A

**BUSINESS ADDRESS:**
- **STREET 1:** 1 PRINCETON MEWS
- **STREET 2:** 167-169 LONDON ROAD
- **CITY:** KINGSTON UPON THAMES SURREY
- **STATE:** X0
- **ZIP:** KT2 6PT
- **BUSINESS PHONE:** 44-7541691673

**MAIL ADDRESS:**
- **STREET 1:** 1 PRINCETON MEWS
- **STREET 2:** 167-169 LONDON ROAD
- **CITY:** KINGSTON UPON THAMES SURREY
- **STATE:** X0
- **ZIP:** KT2 6PT

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**SCHEDULE TO/A**

**Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1)**

**of the Securities Exchange Act of 1934**

**(Amendment No. 17)**

------

**F-STAR THERAPEUTICS, INC.**

(Name of Subject Company)

**SINO BIOPHARMACEUTICAL LIMITED, INVOX PHARMA LIMITED**

**and**

**FENNEC ACQUISITION INCORPORATED**

(Names of Filing Persons (Offerors))

**Common Stock, $0.0001 par value per share**<br> (Title of Class of Securities)

**30315R 107**<br> (CUSIP Number of Class of Securities)

**Tyron Hussey**

**invoX Pharma Limited**

**5 Merchant Square**

**London, United Kingdom, W2 1AY**

**+44 203 786 5144**

(Name, Address and Telephone Number of Person Authorized to Receive Notices and<br> Communications on Behalf of Filing Persons)

*With a copy to:*

**George Casey**

**George Karafotias<br> Shearman & Sterling LLP<br> 599 Lexington Avenue<br> New York, NY 10022<br> (212) 848-4000**

☒ Check box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was
previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid: $14,559 Filing Party: invoX Pharma Limited<br> Form or Registration No.: Schedule TO-T Date Filed: July 7, 2022

☐ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

☒ third-party tender offer subject to Rule 14d-1.

☐ issuer tender offer subject to Rule 13e-4.

☐ going-private transaction subject to Rule 13e-3.

☐ amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

☐ Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

☐ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

This Amendment No. 17 to Schedule TO (together with any exhibits and annexes attached hereto, and as it may be amended or supplemented from time to time, this "**Amendment**") is filed by (i) Fennec Acquisition Incorporated, a Delaware corporation ("**Purchaser**") and a direct wholly-owned subsidiary of invoX Pharma Limited, a private limited company organized under the laws of England and Wales ("**Parent**"), which is a direct wholly-owned subsidiary of Sino Biopharmaceutical Limited, a company organized under the laws of the Cayman Islands ("**SBP**"), (ii) Parent and (iii) SBP, and amends and supplements the Tender Offer Statement on Schedule TO filed with the U.S. Securities and Exchange Commission (the "**SEC**") on July 7, 2022 (together with any amendments and supplements thereto, the "**Schedule TO**") by Purchaser, Parent, and SBP. The Schedule TO relates to the offer by Purchaser to purchase all of the issued and outstanding shares (each, a "**Share**" and collectively, the "**Shares**") of common stock, par value $0.0001 per share, of F-star Therapeutics, Inc., a Delaware corporation (the "**Company**"), for $7.12 per Share, payable net to the holder in cash, without interest, subject to any withholding taxes required by applicable law, and on the terms and subject to the conditions set forth in the Offer to Purchase, dated July 7, 2022 (the "**Offer to Purchase**"), a copy of which is attached as Exhibit (a)(1)(a) to the Schedule TO, and in the accompanying letter of transmittal, a copy of which is attached as Exhibit (a)(1)(b) to the Schedule TO, and which, as each may be amended or supplemented from time to time, collectively constitute the "**Offer**."

Except as otherwise set forth in this Amendment, the information set forth in the Schedule TO remains unchanged and is incorporated herein by reference to the extent relevant to the items in this Amendment. Capitalized terms used but not defined herein have the meanings ascribed to them in the Schedule TO.

***Items 1 through 9; Item 11.***

The Offer to Purchase and Items 1 through 9 and Item 11 of the Schedule TO, to the extent such Items 1 through 9 and Item 11 incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented by adding the following paragraph thereto:

"On March 6, 2023, Purchaser, Parent, and SBP extended the Offer to 5:00 p.m., Eastern Time, on March 8, 2023, unless further extended. The Offer was previously set to expire at 5:00 p.m., Eastern Time, on March 3, 2023. The Expiration Date is being extended to afford the Parties additional time to finalize an agreement necessary to remove CFIUS's Interim Order and allow the transaction to close. The Depositary has advised Purchaser, Parent, and SBP that, as of 5:00 p.m., Eastern Time, on March 3, 2023, 15,540,964 Shares had been validly tendered into and not properly withdrawn from the Offer, representing approximately 70.65% of the outstanding Shares, and an additional approximately 2,054,490 Shares tendered pursuant to a notice of guaranteed delivery.

To afford the Parties additional time to finalize an agreement necessary to remove CFIUS's Interim Order and allow the transaction to close, Purchaser, Parent, and the Company entered into Amendment No. 8 ("**Amendment No. 8**") to the Merger Agreement on March 5, 2023. Amendment No. 8 extends the End Date of the Merger Agreement from "one (1) minute past 11:59 p.m., Eastern Time, on March 7, 2023" to "one (1) minute past 11:59 p.m., Eastern Time, on March 14, 2023.""

***Items 5 through 6; Item 11.***

The Offer to Purchase and Items 5 through 6 and Item 11 of the Schedule TO, to the extent such Items 5 through 6 and Item 11 incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Section 10 — "Background of the Offer; Past Contacts or Negotiations with the Company" of the Offer to Purchase
is hereby amended and supplemented by adding the following paragraphs at the end thereof:

"On March 5, 2023, Purchaser, Parent, and the Company entered into Amendment No. 8 ("**Amendment No. 8**") to the Merger Agreement. Amendment No. 8 extends the End Date of the Merger Agreement from "one (1) minute past 11:59 p.m., Eastern Time, on March 7, 2023" to "one (1) minute past 11:59 p.m., Eastern Time, on March 14, 2023."

Other than as expressly modified pursuant to Amendments Nos. 1 through 8, the Merger Agreement, which was previously filed as Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 23, 2022, remains in full force and effect as originally executed on June 22, 2022. The foregoing description of Amendment No. 8 does not purport to be complete and is subject to, and qualified in its entirety by, the full text of Amendment No. 8 attached as Exhibit (d)(16) hereto and incorporated herein by reference."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Section 11 — "The Merger Agreement; Other Agreements" of the Offer to Purchase is hereby amended and supplemented
by adding the following paragraphs at the end of the subsection titled "Termination":

"As described above, the Merger Agreement may be terminated by either Parent or the Company, subject to certain exceptions, if the Offer Acceptance Time has not occurred on or prior to the End Date. On March 5, 2023, the Company, Purchaser, and Parent entered into Amendment No. 8 to extend the End Date from "one (1) minute past 11:59 p.m., Eastern Time, on March 7, 2023" to "one (1) minute past 11:59 p.m., Eastern Time, on March 14, 2023". The Parties have extended the End Date to afford the Parties additional time to finalize an agreement necessary to remove CFIUS's Interim Order and allow the transaction to close."

***Item 11. Additional Information.***

The Offer to Purchase and Item 11 of the Schedule TO, to the extent such Item 11 incorporates by reference the information contained in the Offer to Purchase, are hereby amended and supplemented as follows:

The information set forth in Section 16 — "Certain Legal Matters; Regulatory Approvals" of the Offer to Purchase is hereby amended and supplemented as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The last paragraph of the subsection titled "Committee on Foreign Investment in the United States" is hereby amended and
supplemented by adding the following paragraph at the end thereof:

"To afford the Parties additional time to finalize an agreement necessary to remove CFIUS's Interim Order and allow the transaction to close, Purchaser, Parent, and the Company entered into Amendment No. 8 ("**Amendment No. 8**") to the Merger Agreement on March 5, 2023. Amendment No. 8 extends the End Date of the Merger Agreement from "one (1) minute past 11:59 p.m., Eastern Time, on March 7, 2023" to "one (1) minute past 11:59 p.m., Eastern Time, on March 14, 2023.""

***Amendments to the Offer to Purchase and the Other Exhibits to the Schedule TO.***

Exhibits (a)(1)(a) through (a)(1)(e) to the Schedule TO (and Items 1 through 9 and Item 11 of the Schedule TO, to the extent such Items 1 through 9 and Item 11 incorporate by reference the information contained in such Exhibits (a)(1)(a) through (a)(1)(e)) are hereby amended and supplemented as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. All references regarding the scheduled expiration of the Offer being "5:00 p.m., Eastern Time, on March 3, 2023" set forth
in the Offer to Purchase, the Letter of Transmittal, Notice of Guaranteed Delivery, Letter to Brokers, Dealers, Commercial Banks, Trust
Companies and Other Nominees, and Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees
are hereby amended and replaced with "5:00 p.m., Eastern Time, on March 8, 2023".

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. All references regarding the End Date of the Merger Agreement being "one (1) minute past 11:59 p.m., Eastern Time, on March
7, 2023" set forth in the Offer to Purchase are hereby amended and replaced with "one (1) minute past 11:59 p.m., Eastern
Time, on March 14, 2023".

 ****

***Item 12. Exhibits.***

Item 12 of the Schedule TO is hereby amended and supplemented to add the following exhibit(s):

(d)(16) Amendment No. 8 to Agreement and Plan of Merger, dated March 5, 2023, among Parent, Purchaser and the Company.\*\*

 ****

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: March 6, 2023

---

| | |
|:---|:---|
| **FENNEC ACQUISITION INCORPORATED** | **FENNEC ACQUISITION INCORPORATED** |
| By: | /s/ Benjamin Toogood<br>|
| Name: | Benjamin Toogood |
| Title: | Chief Executive Officer |
| **INVOX PHARMA LIMITED** | **INVOX PHARMA LIMITED** |
| By: | /s/ Benjamin Toogood<br>|
| Name: | Benjamin Toogood |
| Title: | Chief Executive Officer |
| **SINO BIOPHARMACEUTICAL LIMITED** | **SINO BIOPHARMACEUTICAL LIMITED** |
| By: | /s/ Benjamin Toogood<br>|
| Name: | Benjamin Toogood |
| Title: | Authorized Signatory |

---

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Item 12.** | **Exhibits.** |
| &nbsp;&nbsp;(a)(1)(a) | [Offer to Purchase, dated July 7, 2022.](http://www.sec.gov/Archives/edgar/data/1566373/000110465922077854/tm2219411d1_ex99-a1a.htm)\* |
| &nbsp;&nbsp;(a)(1)(b) | [Form of Letter of Transmittal.](https://www.sec.gov/Archives/edgar/data/1566373/000110465922077854/tm2219411d1_ex99-a1b.htm)\* |
| &nbsp;&nbsp;(a)(1)(c) | [Form of Notice of Guaranteed Delivery.](https://www.sec.gov/Archives/edgar/data/1566373/000110465922077854/tm2219411d1_ex99-a1c.htm)\* |
| &nbsp;&nbsp;(a)(1)(d) | [Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.](https://www.sec.gov/Archives/edgar/data/1566373/000110465922077854/tm2219411d1_ex99-a1d.htm)\*  |
| &nbsp;&nbsp;(a)(1)(e) | [Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.](https://www.sec.gov/Archives/edgar/data/1566373/000110465922077854/tm2219411d1_ex99-a1e.htm)\* |
| &nbsp;&nbsp;(a)(1)(f) | [Summary Advertisement as published in *The New York Times* on July 7, 2022.](https://www.sec.gov/Archives/edgar/data/1566373/000110465922077854/tm2219411d2_ex99-a1f.htm)\* |
| &nbsp;&nbsp;(a)(1)(g) | [Power of Attorney for SBP, dated as of June 22, 2022.](https://www.sec.gov/Archives/edgar/data/1566373/000110465922077854/tm2219411d2_ex99-a1g.htm)\* |
| &nbsp;&nbsp;(a)(5)(a) | [Joint Press Release issued by Parent and the Company on June 23, 2022, attached as Exhibit (a)(5)(a) to the Form SC TO-C filed by Parent with the Securities and Exchange Commission on June 23, 2022 (incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/1566373/000094787122000719/ss1107826_ex99a5a.htm)\* |
| &nbsp;&nbsp;(a)(5)(b) | [Announcement, published by SBP on the Hong Kong Stock Exchange on June 23, 2022, attached as Exhibit (a)(5)(b) to the Form SC TO-C filed by Parent with the Securities and Exchange Commission on June 23, 2022 (incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/1566373/000094787122000719/ss1107826_ex99a5b.htm)\* |
| &nbsp;&nbsp; <br> (a)(5)(c) | <br> [Press Release Announcing Commencement of Tender Offer issued by Parent on July 8, 2022.](https://www.sec.gov/Archives/edgar/data/1566373/000094787122000753/ss1148855_ex99a5c.htm)\*<br>|
| &nbsp;&nbsp;(a)(5)(d) | [Joint Press Release Announcing Extension of the Offer, issued by Parent, SBP and the Company on August 4, 2022.](https://www.sec.gov/Archives/edgar/data/1566373/000094787122000825/ss1219871_ex99a5d.htm)\*  |
| &nbsp;&nbsp;(d)(1) | [Agreement and Plan of Merger, dated June 22, 2022, among SBP, Parent, Purchaser and the Company, attached as Exhibit 2.1 to the Form 8-K filed by the Company with the Securities and Exchange Commission on June 23, 2022 (incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/1566373/000119312522179458/d281525dex21.htm)\* |
| &nbsp;&nbsp;(d)(2) | [Form of Securities Purchase Agreement, by and among Purchaser, Parent, SBP and the Company.](https://www.sec.gov/Archives/edgar/data/1566373/000110465922077854/tm2219411d2_ex99-d2.htm)\* |
| &nbsp;&nbsp;(d)(3) | [Form of Tender and Support Agreement, dated June 22, 2022, among Parent, Purchaser and the stockholders of the Company party thereto, attached as Exhibit 99.2 to the Form 8-K filed by the Company with the Securities and Exchange Commission on June 23, 2022 (incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/1566373/000119312522179458/d281525dex992.htm)\* |
| &nbsp;&nbsp; <br> (d)(4) | <br> [Confidentiality and Non-Disclosure Agreement, dated as of December 17, 2021, by and between SBP and the Company.](https://www.sec.gov/Archives/edgar/data/1566373/000110465922077854/tm2219411d2_ex99-d4.htm)\* |
| &nbsp;&nbsp; <br> (d)(5) | <br> [Transition Services Agreement and Settlement Agreement, dated as of June 22, 2022, by and among F-star Therapeutics Limited, Parent and Eliot Forster.](https://www.sec.gov/Archives/edgar/data/1566373/000110465922077854/tm2219411d2_ex99-d5.htm)\* |
| &nbsp;&nbsp; <br> (d)(6) | <br> [Amendment to Employment Agreement, dated as of June 22, 2022, by and among F-star Therapeutics Limited, Parent and Neil Brewis.](https://www.sec.gov/Archives/edgar/data/1566373/000110465922077854/tm2219411d2_ex99-d6.htm)\*<br>|
| &nbsp;&nbsp;(d)(7) | [Letter Agreement, dated July 25, 2022, by and between Parent and Darlene Deptula-Hicks.](https://www.sec.gov/Archives/edgar/data/1566373/000094787122000799/ss1188987_ex99d7.htm)\*  |
| &nbsp;&nbsp;(d)(8) | [Letter Agreement, dated July 25, 2022, by and between Parent and Louis Kayitalire.](https://www.sec.gov/Archives/edgar/data/1566373/000094787122000799/ss1188987_ex99d8.htm)\* |
| &nbsp;&nbsp;(d)(9) | [Amendment No. 1 to Agreement and Plan of Merger, dated November 20, 2022, among Parent, Purchaser and the Company, attached as Exhibit 2.1 to the Form 8-K filed by the Company with the Securities and Exchange Commission on November 21, 2022 (incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/1566373/000119312522289465/d391750dex21.htm)\* |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;(d)(10) | [Amendment No. 2 to Agreement and Plan of Merger, dated December 19, 2022, among Parent, Purchaser and the Company.](https://www.sec.gov/Archives/edgar/data/1566373/000094787122001247/ss1613625_ex99d10.htm)\* |
| &nbsp;&nbsp;(d)(11) | [Amendment No. 3 to Agreement and Plan of Merger, dated December 20, 2022, among Parent, Purchaser and the Company.](https://www.sec.gov/Archives/edgar/data/1566373/000094787122001250/ss1620806_ex99d11.htm)\*<br>|
| &nbsp;&nbsp;(d)(12) | [Amendment No. 4 to Agreement and Plan of Merger, dated December 30, 2022, among Parent, Purchaser and the Company.](https://www.sec.gov/Archives/edgar/data/1566373/000094787122001265/ss1637705_ex99d12.htm)\* |
| &nbsp;&nbsp;(d)(13) | [Amendment No. 5 to Agreement and Plan of Merger, dated January 31, 2023, among Parent, Purchaser and the Company.](https://www.sec.gov/Archives/edgar/data/1566373/000094787123000108/ss1723744_ex99d13.htm)\* |
| &nbsp;&nbsp;(d)(14) | [Amendment No. 6 to Agreement and Plan of Merger, dated February 9, 2023, among Parent, Purchaser and the Company.](https://www.sec.gov/Archives/edgar/data/1566373/000094787123000148/ss1752098_ex99d14.htm)\* |
| &nbsp;&nbsp;(d)(15) | [Amendment No. 7 to Agreement and Plan of Merger, dated February 22, 2023, among Parent, Purchaser and the Company](https://www.sec.gov/Archives/edgar/data/1566373/000094787123000218/ss1798245_ex99d15.htm).\* |
| &nbsp;&nbsp;(d)(16) | [Amendment No. 8 to Agreement and Plan of Merger, dated March 5, 2023, among Parent, Purchaser and the Company.](ss1834599_ex99d16.htm)\*\* |
| &nbsp;&nbsp;(g) | Not applicable. |
| &nbsp;&nbsp;(h) | Not applicable. |
| &nbsp;&nbsp;107 | [Filing Fee Table](https://www.sec.gov/Archives/edgar/data/1566373/000110465922077854/tm2219411d2_ex-filingfees.htm).\* |
| &nbsp;&nbsp; ____________________<br>\*Previously filed.<br> \*\*Filed herewith. | &nbsp;&nbsp; ____________________<br>\*Previously filed.<br> \*\*Filed herewith. |

---

## Ex-99

**Exhibit (d)(16)**

*Execution Version*

**<u>AMENDMENT NO. 8 TO AGREEMENT AND PLAN OF MERGER</u>**

This AMENDMENT NO. 8 TO AGREEMENT AND PLAN OF MERGER (this "***Amendment***") is entered into as of March 5, 2023, by and among invoX Pharma Limited, a private limited company under the laws of England and Wales ("***Parent***"), Fennec Acquisition Incorporated, a Delaware corporation and a wholly owned subsidiary of Parent ("***Purchaser***"), and F-star Therapeutics, Inc., a Delaware corporation (the "***Company***" and together with Parent and Purchaser, the "***Parties***").

WHEREAS, the Parties entered into that certain Agreement and Plan of Merger, dated as of June 22, 2022 (the "***Merger Agreement***"), by and among the Parties and Sino Biopharmaceutical Limited, a company organized under the laws of the Cayman Islands ("***Guarantor***"), as amended by that certain Amendment No. 1 to the Merger Agreement, dated as of November 20, 2022, by and among the Parties, as further amended by that certain Amendment No. 2 to the Merger Agreement, dated as of December 19, 2022, by and among the Parties, as further amended by that certain Amendment No. 3 to the Merger Agreement, dated as of December 20, 2022, by and among the Parties, as further amended by that certain Amendment No. 4 to the Merger Agreement, dated as of December 30, 2022, by and among the Parties, as further amended by that certain Amendment No. 5 to the Merger Agreement, dated as of January 31, 2023, as further amended by that certain Amendment No. 6 to the Merger Agreement, dated as of February 9, 2023, by and among the Parties, and as further amended by that certain Amendment No. 7 to the Merger Agreement, dated as of February 22, 2023, by and among the Parties;

WHEREAS, capitalized terms used but not defined herein shall have the meanings assigned to them in the Merger Agreement;

WHEREAS, pursuant to Section 9.1 of the Merger Agreement, prior to the Effective Time (as defined in the Merger Agreement) the Merger Agreement may be amended with the approval of each of Parent, Purchaser, and the board of directors of the Company at any time (the "***Requisite Parties***"); and

WHEREAS, the Requisite Parties desire to amend the Merger Agreement pursuant to Section 9.1 of the Merger Agreement as set forth herein.

NOW, THEREFORE, in consideration of the covenants and representations set forth herein and therein, and for other good and valuable consideration, the Requisite Parties hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **<u>Amendment to Section 8.1(e) of the Merger Agreement</u>**. Section 8.1(e) of the Merger Agreement is hereby amended and restated in its entirety as follows:

"by either Parent or the Company if the Offer Acceptance Time shall not have occurred on or prior to one (1) minute past 11:59 p.m., Eastern Time, on March 14, 2023 (such date, the "***End Date***");"

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. **<u>No Other Amendments</u>**. Each future reference to "this Agreement" and other similar references set forth in the Merger Agreement shall refer to the Merger Agreement as modified by this Amendment. Except as and to the extent expressly modified by this Amendment, the Merger Agreement is not otherwise being amended, modified or supplemented and shall remain in full force and effect in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **<u>General Provisions</u>**. Article 9 of the Merger Agreement shall apply to this Amendment *mutatis mutandis* and to the Merger Agreement as modified by this Amendment, taken together as a single agreement, reflecting the terms as modified hereby.

[S*ignature pages follow*]

IN WITNESS WHEREOF, the Requisite Parties have caused this Amendment to be signed, all as of the date first written above.

---

| | |
|:---|:---|
| **PARENT:** | **PARENT:** |
| invoX Pharma Limited | invoX Pharma Limited |
| By: | /s/ Benjamin Toogood<br>|
| Name: | Benjamin Toogood |
| Title: | Chief Executive Officer |

---

[*Signature Page to Amendment No. 8 to Agreement and Plan of Merger*]

IN WITNESS WHEREOF, the Requisite Parties have caused this Amendment to be signed, all as of the date first written above.

---

| | |
|:---|:---|
| **PURCHASER:** | **PURCHASER:** |
| FENNEC ACQUISITION INCORPORATED | FENNEC ACQUISITION INCORPORATED |
| By: | /s/ Benjamin Toogood<br>|
| Name: | Benjamin Toogood |
| Title: | Chief Executive Officer |

---

[*Signature Page to Amendment No. 8 to Agreement and Plan of Merger*]

IN WITNESS WHEREOF, the Requisite Parties have caused this Amendment to be signed, all as of the date first written above.

---

| | |
|:---|:---|
| **COMPANY:** | **COMPANY:** |
| F-STAR THERAPEUTICS, INC. | F-STAR THERAPEUTICS, INC. |
| By: | /s/ Eliot Forster, Ph.D.<br>|
| Name: | Eliot Forster, Ph.D. |
| Title: | Chief Executive Officer |

---

[*Signature Page to Amendment No. 8 to Agreement and Plan of Merger*]